In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Smaller studies and animal research had hinted it could help with brain inflammation or slow cognitive decline, but larger trials were needed to prove it.

Imagine if losing weight were as simple as swallowing a daily pill-no needles, no injections and no anxiety. If you're among ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

Semaglutide belongs to this class of drugs. They were initially developed to control blood sugar in diabetics, but researchers noticed something unexpected: they also triggered substantial weight loss ...

Weight loss drugs like Wegovy and Ozempic have helped millions in their weight loss (and diabetes) journeys. Now, Novo Nordisk—the creator of Wegovy—has published results of a once-daily oral ...

Small-molecule technology could soon make easy-to-take GLP-1 pills a reality. Experts expect next-generation diabetes and weight loss drugs to result in greater weight loss and more health benefits.